CLINICAL USE

Hormone dependent metastatic breast cancer in post-menopausal women

DOSE IN NORMAL RENAL FUNCTION

60 mg daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 406
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : >99.5
  • %Excreted unchanged in urine &nbsp &nbsp : 10% as metabolites

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp : 580 litres

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : 5 days/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unlikely to be dialysed.

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unlikely to be dialysed.
  • HDF/high flux &nbsp : Unknown dialysability.
  • CAV/VVHD &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Anticoagulants: enhanced anticoagulant effect of coumarins

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    As it is not renally excreted, it may be possible to prescribe the normal dose in dialysis patients, although it has not previously been used in this population .
    Tags:

    • Related News

    ffddfd

    Hyperlipidemia